Possible role of neocytolysis in anemia in hemodialysis patients with darbepoetin alfa or continuous erythropoietin receptor activator

被引：3
作者：
Daimon, Shoichiro [1 ]
机构：
[1] Daimon Clin Internal Med Nephrol & Dialysis, Dept Nephrol, Oshino 1-400, Nonoichi, Ishikawa 9218802, Japan
来源：
THERAPEUTIC APHERESIS AND DIALYSIS | 2020年 / 24卷 / 05期
关键词：
D O I：
10.1111/1744-9987.13537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：602 / 606
页数：5
相关论文
共 7 条
[1]   Implications of neocytolysis for optimal management of anaemia in chronic kidney disease [J].
Alfrey, Clarence P. ;
Fishbane, Steven .
NEPHRON CLINICAL PRACTICE, 2007, 106 (04) :149-156
[2]   Control of red blood cell mass in spaceflight [J].
Alfrey, CP ;
Udden, MM ;
LeachHuntoon, C ;
Driscoll, T ;
Pickett, MH .
JOURNAL OF APPLIED PHYSIOLOGY, 1996, 81 (01) :98-104
[3]   Comparison of the Effect of the Same Dose of a 4-Weekly Continuous Erythropoietin Receptor Activator Administered Once Every 2 or 4 Weeks in Hemodialysis Patients [J].
Daimon, Shoichiro .
THERAPEUTIC APHERESIS AND DIALYSIS, 2014, 18 (05) :518-520
[4]   Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in patients with chronic kidney disease [J].
Macdougall, Iain C. ;
Robson, Richard ;
Opatrna, Sylvie ;
Liogier, Xavier ;
Pannier, Anne ;
Jordan, Paul ;
Dougherty, Frank C. ;
Reigner, Bruno .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06) :1211-1215
[5]   Comparison of 2-Week Versus 4-Week Dosing Intervals of Epoetin Beta Pegol on Erythropoiesis and Iron Metabolism in Hemodialysis Patients [J].
Morikami, Yuki ;
Fujimori, Akira ;
Okada, Shioko ;
Kumei, Mai ;
Mizobuchi, Noriko ;
Sakai, Makoto .
THERAPEUTIC APHERESIS AND DIALYSIS, 2014, 18 (05) :414-420
[6]  
Polenakovic M, 1996, J AM SOC NEPHROL, V7, P1178
[7]   Neocytolysis contributes to the anemia of renal disease [J].
Rice, L ;
Alfrey, CP ;
Driscoll, T ;
Whitley, CE ;
Hachey, DL ;
Suki, W .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (01) :59-62
1